Anika Showcases Highly Differentiated Joint Preservation and Restoration Portfolio at the 2023 AOSSM Annual Meeting
12 July 2023 - 11:00PM
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint
preservation company focused on early intervention
orthopedics, today announced it will highlight core products from
its joint preservation and restoration portfolio at the 2023
American Orthopaedic Society for Sports Medicine (AOSSM) Annual
Meeting on July 13-16th in Washington, D.C. As Anika continues to
establish itself as a global market leader in joint preservation,
the company will feature its Tactoset Injectable Bone Substitute
for hardware augmentation, the X-Twist Fixation System, and the
OVOMotion® with Inlay Glenoid Total Shoulder Arthroplasty (TSA)
System at booth #311 during the conference.
“We are excited to once again be joining the sports medicine
community at the 2023 AOSSM Annual Meeting. Anika’s focused and
differentiated product portfolio in sports medicine with
regenerative solutions continues to expand to best address the
ever-evolving needs of surgeons and their patients. We look forward
to sharing these latest highlights,” said Cheryl R. Blanchard,
Ph.D., Anika’s President and CEO. “At this year’s event, we will
put the spotlight on our shoulder portfolio including the X-Twist
Fixation System, Tactoset for augmentation of anchors in poor
quality bone, and the long-established and data-backed OVOMotion
with Inlay Glenoid TSA System. We’re continuing to build upon this
existing momentum to bring meaningful advancements to the sports
medicine market.”
During the 2022 AOSSM Annual Meeting, Anika and its
Tactoset Injectable Bone Substitute for hardware
augmentation took home AOSSM’s prestigious Accelerating
the Cutting Edge (ACE) Award. At each year’s conference, the ACE
Award recognizes the most cutting-edge, new innovations among those
exhibited. Last year’s award celebrated the innovative nature of
Tactoset, an injectable, settable, calcium phosphate-based bone
graft substitute that incorporates Anika’s core hyaluronic acid
(HA) technology, and its value in hardware augmentation for poor
quality bone.
“Bone quality is a critical factor when placing load bearing
anchors in bone, and the area that the hardware is in or near is
often weaker with inferior quality bone or insufficiency fractures.
Fundamentally, shoulders, knees and other joints that require
surgery are often associated with either osteoporotic bone and/or
lower quality bone which significantly increases the potential for
pain, hardware failure such as suture anchor pullout, and
inferior patient outcomes,” said Misty Suri, MD from Ochsner
Health in New Orleans, in 2022 after Tactoset was selected for the
ACE Award. Dr. Misty Suri is scheduled to present his postoperative
data on Tactoset during the 2023 AOSSM Annual Meeting.
Anika recently received a 510(k) clearance for Tactoset with the
ability to combine with autologous bone marrow aspirate
(BMA). BMA is a rich source of various cellular and molecular
components which have demonstrated positive effects on tissue
regeneration in musculoskeletal injuries. This indication increases
Tactoset’s clinical and commercial reach by combining BMA with
Tactoset for the treatment of bone defects such as osteoporotic
bone, cysts, and insufficiency fractures. Additionally, Anika
signed a U.S. distribution agreement earlier this year to
distribute the Marrow Cellution™ Bone Marrow Aspiration Needle.
This system utilizes a patented technology that combines aspiration
and cannula motion to maximize cell recovery, while eliminating the
need to remove materials from the sterile field for centrifuge
processing. This drives time-saving efficiencies and mitigates risk
to the patient compared to competitive systems.
Additionally featured, the X-Twist Fixation
System, now in full market release, is an open
architecture platform of suture anchors designed to be mechanically
strong1, easy to use, and support healing. This cornerstone system
affords surgeons a variety of knotless and knotted soft tissue
fixation options in a single anchor platform. The feature-rich
design includes venting intended to support cellular infiltration
through the anchor to promote bony ingrowth; a double helix thread
that allows fast and easy deployment; the ability to support the
surgeon’s preferred combination of multiple sliding suture or tape
configurations; and the unique X-Spline™ drive technology which
provides more torque transfer for easy and fast anchor
insertion.
Throughout the 2023 AOSSM Annual Meeting, there will be ample
opportunities to learn more about Anika’s featured products at the
Anika booth #311 through Ask the Expert sessions.
A Keystone Product Theater presentation featuring Misty Suri,
MD, entitled “Rotator Cuff Repair Postoperative Outcomes When
Augmenting with Tactoset” will take place on Friday, July 14, 2023
from 10:15 AM – 10:45 AM located at the back of the exhibit hall in
the Product Theater Booth. Following the Product Theater, Dr. Suri
will be present at the Anika booth #311 until 1:00 PM for questions
and further information related to his post-op data and Tactoset
for hardware augmentation. Later that evening, Anika is also
hosting an educational dinner symposium at 6:00PM where Dr. Suri
will present postoperative Tactoset for hardware augmentation data.
There are limited spots available, and it is recommended that you
RSVP early here: https://bit.ly/AnikaAOSSM
1. Preclinical data on file. Results may not correlate to
clinical performance.
About AnikaAnika Therapeutics, Inc. (NASDAQ:
ANIK), is a global joint preservation company that creates and
delivers meaningful advancements in early intervention orthopedic
care. Leveraging our core expertise in hyaluronic acid and implant
solutions, we partner with clinicians to provide minimally invasive
products that restore active living for people around the world.
Our focus is on high opportunity spaces within orthopedics,
including Osteoarthritis Pain Management, Regenerative Solutions,
Sports Medicine and Arthrosurface Joint Solutions, and our products
are efficiently delivered in key sites of care, including
ambulatory surgery centers. Anika’s global operations are
headquartered outside of Boston, Massachusetts. For more
information about Anika, please visit www.anika.com.
ANIKA, ANIKA THERAPEUTICS, OVOMOTION, TACTOSET, X-SPLINE,
X-TWIST, and the Anika logo are trademarks of Anika Therapeutics,
Inc. or its subsidiaries. MARROW CELLUTION is a trademark of
EndoCellutions, LLC.
For Investor Inquiries:Anika Therapeutics,
Inc.Mark Namaroff, 781-457-9287Vice President, Investor Relations,
ESG and Corporate Communicationsinvestorrelations@anika.com
For Media Inquiries:GreenoughChristine
Williamson, 617-922-1289Senior Vice
Presidentcwilliamson@greenough.biz
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Apr 2024 to May 2024
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From May 2023 to May 2024